SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) February 17,2000
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
Biocontrol Technology, Inc. announced today that its
subsidiary, IDT, Inc., in conjunction with HemoCleanse,
Inc. located in Lafayette, Indiana, has received FDA
approval and Institutional Review Approval from the
University of Texas Medical Branch at Galveston to
continue a human clinical trial to treat patients with
non-small cell lung cancer (NSCLC). The objective of
the clinical trial is to evaluate the ThermoChem
technology as a delivery system for Perfusion-Induced
Systemic Hyperthermia in the treatment of non-small
cell lung cancer with regard to patient selection,
tumor response, patient performance status, and
patient survival.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information and Exhibits.
(a) Financial Statements and Businesses Acquired - Not Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - Press Release.
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: February 17, 2000
BICO
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
Investors Media
Diane McQuaide Susan Taylor
1.412.429.0673 phone 1.412.429.0673 phone
1.412.279.9690 fax 1.412.279.5041 fax
BIOCONTROL TECHNOLOGY, INC. SUBSIDIARY, IDT, RECEIVES FDA APPROVAL TO CONTINUE
LUNG CANCER STUDY AT THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON
Pittsburgh, PA - February 17, 2000 - Biocontrol Technology,
Inc. (OTCBB:BICO) announced today that its subsidiary, IDT,
Inc., in conjunction with HemoCleanse, Inc. located in Lafayette,
Indiana, has received FDA approval and Institutional Review
Approval from the University of Texas Medical Branch at Galveston
to continue a human clinical trial to treat patients with non-
small cell lung cancer (NSCLC).
The clinical trial will utilize the ThermoChem technology
and disposables to deliver Perfusion-Induced Systemic
Hyperthermia (PISH), a therapy in which core body temperature is
raised to 42 C (107.6 F) for two hours by direct extracorporeal
(outside of the body) heating of the blood. Non-small cell lung
cancer is a combination of at least three malignant cell
structures found in the tissues of the lungs. Lung cancer
remains a major cause of cancer morbidity and mortality in the
United States.
IDT completed the first phase of the FDA approved study,
which involved five patients in July 1998. That phase of the
study involved patients with Stage IV non-small cell lung cancer
where cancer had spread to other parts of the body. Results of
that study are pending publication.
In this most recent approval, the FDA allowed Stage IIIb
patients to be included. Stage IIIb is usually non-operative
cancer that has spread to the chest wall or diaphragm near the
lung or cancer that has spread to the lymph nodes in the area
that separates the two lungs or to the lymph nodes on the other
side of the chest or in the neck.
The objective of the clinical trial is to evaluate the
ThermoChem technology as a delivery system for Perfusion-Induced
Systemic Hyperthermia in the treatment of non-small cell lung
cancer with regard to patient selection, tumor response, patient
performance status, and patient survival.
In Perfusion-Induced Systemic Hyperthermia, the ThermoChem
technology is composed of the ThermoChem-HT SystemT and
ThermoChem-SB SystemT. The ThermoChem-HT System heats and
circulates the blood while maintaining core body temperature, and
ThermoChem-SB System balances blood chemistries on a "real-time"
basis and removes toxins from the blood. The Company believes
this interface between two systems is essential to safely deliver
Perfusion-Induced Systemic Hyperthermia.
IDT has been developing the ThermoChem technology as a safe
delivery system for whole body and regional hyperthermia since
1992. The FDA recently cleared the ThermoChem-HT System for
marketing where the intended use is to raise the core temperature
of the peritoneum to 42 C (107.6 F) by continuously lavaging
(bathing) the peritoneum with sterile solution. Intraperitoneal
hyperthermia is part of an operative procedure used to treat
patients with advanced ovarian and gastrointestinal cancer.
Biocontrol Technology has its corporate offices in
Pittsburgh, PA and is involved in the development and
manufacture of biomedical devices and environmental
products. IDT, Inc., a subsidiary of Biocontrol also located
in Pittsburgh, PA, holds exclusive worldwide marketing
rights to the ThermoChem-HT technology and related
disposables for regional hyperthermia and the ThermoChem
technology and related disposables for whole body
hyperthermia.
WEBSITE: www.bico.com
INVESTOR RELATIONS NEWSLINE NUMBER: 1.800.357.6204
